Trial Profile
A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Fedovapagon (Primary)
- Indications Nocturia
- Focus Registrational; Therapeutic Use
- Acronyms EQUINOC
- Sponsors Vantia Therapeutics
- 03 Oct 2017 Results presented in a Vantia Therapeutics Media Release.
- 03 Oct 2017 Primary endpoint has been met. (Change in mean patient reported nocturia bother score), according to a Vantia Therapeutics media release.
- 03 Oct 2017 Primary endpoint has been met (Change in the mean number of night-time voids), according to a Vantia Therapeutics media release.